<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00066547</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000316264</org_study_id>
    <secondary_id>UCLA-0212097</secondary_id>
    <secondary_id>ANTISOMA-TOPCAT</secondary_id>
    <secondary_id>ANTISOMA-ASM-THEREX-01</secondary_id>
    <nct_id>NCT00066547</nct_id>
  </id_info>
  <brief_title>Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy</brief_title>
  <official_title>An Open Label Phase I/II Study of Humanized Human Milk Fat Globule-1 (THEREX) in Patients With Locally Advanced or Metastatic Breast Cancer Following Prior Anthracycline and Taxane Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonsson Comprehensive Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver&#xD;
      tumor-killing substances to them without harming normal cells.&#xD;
&#xD;
      PURPOSE: Phase I/II trial to study the effect of monoclonal antibody therapy on the body and&#xD;
      its effectiveness in treating women who have locally advanced or metastatic breast cancer&#xD;
      that was previously treated with combination chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine the safety and tolerability of monoclonal antibody HuHMFG1 in women with&#xD;
           locally advanced or metastatic breast cancer previously treated with anthracycline and&#xD;
           taxane-based therapy.&#xD;
&#xD;
        -  Determine the maximum tolerated dose and appropriate schedule of this drug in these&#xD;
           patients.&#xD;
&#xD;
        -  Determine the pharmacokinetic profile of this drug in these patients.&#xD;
&#xD;
        -  Determine the tumor response rate, progression-free survival, and median survival of&#xD;
           patients treated with this drug.&#xD;
&#xD;
        -  Analyze immunological markers for evaluation of disease status (e.g., in vitro analysis&#xD;
           of antibody-dependent cellular cytotoxicity, natural killer cell activity, complement&#xD;
           depletion, and tumor markers CA 15.3 and CEA) in patients treated with this drug.&#xD;
&#xD;
      OUTLINE: This is a dose-escalation, open-label, nonrandomized, multicenter study.&#xD;
&#xD;
        -  Phase I: Patients receive monoclonal antibody HuHMFG1 IV over 1-3 hours once every 3&#xD;
           weeks for doses 1 and 2. All subsequent dose intervals are based on individual half-life&#xD;
           value of the drug. Patients receive at least 6 doses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Cohorts of 3-6 patients receive escalating doses of monoclonal antibody HuHMFG1 until the&#xD;
      maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at&#xD;
      which at least 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.&#xD;
&#xD;
        -  Phase II:Patients receive monoclonal antibody HuHMFG1 as above at the MTD. Patients are&#xD;
           followed at 28 days.&#xD;
&#xD;
      PROJECTED ACCRUAL: Approximately 3-40 patients (3-15 patients for phase I and 19-25 patients&#xD;
      for phase II) will be accrued for this study within approximately 12 months.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>May 2003</start_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <condition>Breast Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>monoclonal antibody HuHMFG1</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Histologically or cytologically confirmed breast cancer&#xD;
&#xD;
               -  Locally advanced or metastatic disease&#xD;
&#xD;
               -  No inflammatory breast cancer&#xD;
&#xD;
          -  Polymorphic epithelial mucin (PEM) antigen overexpression by immunohistochemistry&#xD;
&#xD;
          -  Previously treated with an anthracycline and a taxane in any combination for breast&#xD;
             cancer&#xD;
&#xD;
               -  No more than 2 prior chemotherapy regimens, including adjuvant /neoadjuvant&#xD;
                  therapy&#xD;
&#xD;
               -  No more than 1 prior regimen for distant metastatic disease&#xD;
&#xD;
               -  Any number of prior hormonal or biologic therapy regimens allowed&#xD;
&#xD;
          -  Measurable disease&#xD;
&#xD;
               -  At least one unidimensionally measurable lesion not previously irradiated&#xD;
&#xD;
               -  The following are not considered measurable lesions:&#xD;
&#xD;
                    -  Bone&#xD;
&#xD;
                    -  Leptomeningeal disease&#xD;
&#xD;
                    -  Ascites&#xD;
&#xD;
                    -  Pleural/pericardial effusion&#xD;
&#xD;
                    -  Lymphangitis cutis/pulmonis&#xD;
&#xD;
                    -  Abdominal masses not confirmed and followed by imaging techniques&#xD;
&#xD;
                    -  Cystic lesions&#xD;
&#xD;
          -  No metastases accessible to complete surgical resection&#xD;
&#xD;
          -  No CNS metastasis by CT scan&#xD;
&#xD;
          -  Hormone receptor status:&#xD;
&#xD;
               -  Not specified&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
        Age&#xD;
&#xD;
          -  18 and over&#xD;
&#xD;
        Sex&#xD;
&#xD;
          -  Female&#xD;
&#xD;
        Menopausal status&#xD;
&#xD;
          -  Not specified&#xD;
&#xD;
        Performance status&#xD;
&#xD;
          -  WHO 0-2&#xD;
&#xD;
        Life expectancy&#xD;
&#xD;
          -  At least 4 months&#xD;
&#xD;
        Hematopoietic&#xD;
&#xD;
          -  Hemoglobin at least 10 g/dL&#xD;
&#xD;
          -  Neutrophil count at least 1,500/mm^3&#xD;
&#xD;
          -  Platelet count at least 100,000/mm^3&#xD;
&#xD;
        Hepatic&#xD;
&#xD;
          -  Bilirubin no greater than 1.5 mg/dL&#xD;
&#xD;
          -  ALT and AST no greater than 2.5 times upper limit of normal (ULN) (less than 5 times&#xD;
             ULN if liver metastases are present)&#xD;
&#xD;
        Renal&#xD;
&#xD;
          -  Creatinine no greater than 1.5 times ULN OR&#xD;
&#xD;
          -  Creatinine clearance greater than 60 mL/min&#xD;
&#xD;
          -  No hyperuricemia (uric acid at least 1.25 times ULN)&#xD;
&#xD;
          -  No hypercalcemia (calcium at least 11.5 mg/dL [corrected for serum albumin])&#xD;
&#xD;
        Cardiovascular&#xD;
&#xD;
          -  LVEF at least 45% by MUGA or echocardiogram within the past 4 weeks&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception during and for 3-6 months after&#xD;
             study participation&#xD;
&#xD;
          -  No other prior malignancy within the past 5 years except adequately treated&#xD;
             nonmelanoma skin cancer or cervical intraepithelial neoplasia&#xD;
&#xD;
          -  No other concurrent uncontrolled comorbid illness that represents unacceptable risk in&#xD;
             the opinion of the investigator&#xD;
&#xD;
          -  No legal incapacity&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
        Biologic therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 2 weeks since prior growth factors to aid hematologic recovery&#xD;
&#xD;
          -  No other concurrent immunotherapy&#xD;
&#xD;
        Chemotherapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  More than 4 weeks since prior cytotoxic chemotherapy&#xD;
&#xD;
          -  No concurrent chemotherapy for metastatic breast cancer&#xD;
&#xD;
        Endocrine therapy&#xD;
&#xD;
          -  See Disease Characteristics&#xD;
&#xD;
          -  No concurrent endocrine therapy for metastatic breast cancer&#xD;
&#xD;
          -  No concurrent chronic corticosteroid therapy&#xD;
&#xD;
          -  No concurrent high-dose corticosteroids&#xD;
&#xD;
        Radiotherapy&#xD;
&#xD;
          -  More than 4 weeks since prior radiotherapy except for palliation&#xD;
&#xD;
          -  No concurrent antitumor radiotherapy except for palliation&#xD;
&#xD;
        Surgery&#xD;
&#xD;
          -  More than 4 weeks since prior major surgery&#xD;
&#xD;
        Other&#xD;
&#xD;
          -  More than 2 weeks since prior blood transfusions to aid hematologic recovery&#xD;
&#xD;
          -  No participation in any other investigational drug study&#xD;
&#xD;
          -  No other concurrent investigational drugs&#xD;
&#xD;
          -  No other concurrent antitumor therapy&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark D. Pegram, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jonsson Comprehensive Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jonsson Comprehensive Cancer Center, UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095-1781</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2004</verification_date>
  <study_first_submitted>August 6, 2003</study_first_submitted>
  <study_first_submitted_qc>August 6, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 7, 2003</study_first_posted>
  <last_update_submitted>December 3, 2013</last_update_submitted>
  <last_update_submitted_qc>December 3, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 4, 2013</last_update_posted>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IIIA breast cancer</keyword>
  <keyword>stage IIIB breast cancer</keyword>
  <keyword>stage IIIC breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

